.png)
.png)
Business Opportunity: Advance your workforce with a Bioscience Degree Apprenticeship
Manchester Metropolitan University have opened applications for the Laboratory Science Degree Apprenticeships in Bioscience. New cohorts are set to begin in September.
Poolbeg Pharma plc announces exclusive option agreement to acquire Orphan Drug Candidate for Behçet's Disease
Poolbeg Pharma plc announces that it has entered into an exclusive 12-month option agreement with Silk Road Therapeutics Inc, for a nominal fee, to acquire a novel topical muco-adherent formulation of Pentoxifylline (tPTX) for the treatment of oral ulcers in patient's suffering from Behçet's Disease.
Significant POLB 001 patent granted in United States
Poolbeg Pharma, a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that, further to its announcement on 20 March 2024, the Company has received the fully granted patent from the US Patent Office for its Immunomodulator II patent application.
MHRA’s AI regulatory strategy ensures patient safety and industry innovation into 2030
The Medicines and Healthcare products Regulatory Agency (MHRA) has today set out its strategic approach to AI. The MHRA welcomed the publication of the Government’s white paper ‘A pro-innovation approach to AI regulation’, published in 2023, and have taken significant steps in the past 12 months to adopt its recommendations in the work we do based on five key strategic principles.
Earlham Institute spinout TraitSeq to transform agricultural sector
A new spin-out company is set to transform the agricultural sector by revolutionising plant and animal breeding, as well as the development of inputs such as agrochemicals, biostimulants, biologicals, and plant nutrients.
Rinri Therapeutics announces new Chair as it approaches first clinical trial
Rinri Therapeutics is pleased to announce the appointment of David Hipkiss as its new Independent Chair. This strategic move comes at a pivotal time as the company prepares to initiate first-in-human trials for its lead asset, Rincell-1.
Jim Faulkner, Nicole Mather and Carolyn Porter join the Cell and Gene Therapy Catapult as Non-Executive Directors
London, United Kingdom, 29 April 2024: The Cell and Gene Therapy Catapult (CGT Catapult), an independent innovation and technology organisation specialising in the advancement of the cell and gene therapy industry, has appointed three new Non-Executive Directors to its board: Jim Faulkner; Nicole Mather; and Carolyn Porter.
Abzena launches EpiScreen® 2.0, a next-generation immunogenicity tool for de-risking the development of complex biologics
Abzena has announced the launch of its enhanced hashtag#bioassay platform EpiScreen® 2.0, a comprehensive suite of assays that predict and evaluate potential risks of preclinical hashtag#immunogenicity in protein, antibody, and gene therapy therapeutics.
University of Oxford spin-out revealed as winner of ‘Golden Ticket’ programme for planetary health innovations
University of Oxford spin-out HydRegen has been revealed as the winner of a programme designed to recognise innovations in planetary health created by Pioneer Group in partnership with CPI.
CHAIN Biotech collaborates with German Cancer Research Center on development of a novel oncology vaccine
CHAIN Biotechnology Ltd and the German Cancer Research Center (DKFZ) have signed an agreement to collaborate on the development of therapeutic cancer vaccines for indications caused by Human Papillomavirus (HPV).